Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 360,824 | 420,512 | 428,266 | 220,805 | 242,455 |
| Receivables | 4,955 | 3,723 | 2,740 | 2,686 | 2,640 |
| TOTAL | $380,186 | $431,312 | $439,756 | $231,298 | $253,562 |
| Non-Current Assets | |||||
| PPE Net | 4,085 | 3,097 | 3,025 | 2,890 | 2,961 |
| Intangibles | 4,064 | 4,168 | 4,296 | 3,950 | 4,108 |
| Other Non-Current Assets | 1,443 | 1,330 | 1,367 | 331 | 334 |
| TOTAL | $9,591 | $8,595 | $8,688 | $7,172 | $7,402 |
| Total Assets | $389,777 | $439,907 | $448,444 | $238,470 | $260,964 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 36,068 | 43,666 | 21,404 | 26,865 | 23,025 |
| TOTAL | $36,077 | $43,696 | $21,404 | $26,865 | $23,377 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | N/A | 111 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $36,077 | $43,696 | $21,404 | $26,865 | $23,377 |
| Shareholders' Equity | |||||
| Common Shares | 6,563 | 6,701 | 6,855 | 5,614 | 5,740 |
| Retained earnings | -420,117 | -390,412 | -374,396 | -297,506 | 208,377 |
| Other shareholders' equity | 41,334 | 37,773 | 33,740 | 25,747 | 23,470 |
| TOTAL | $353,699 | $396,212 | $427,040 | $211,605 | $237,587 |
| Total Liabilities And Equity | $389,777 | $439,907 | $448,444 | $238,470 | $260,964 |